Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GKOSNASDAQ:NARINYSE:STVNNYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGKOSGlaukos$92.21-2.6%$94.30$77.10▼$163.71$5.27B0.83681,471 shs901,865 shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.31 million shsN/ASTVNStevanato Group€24.42+3.2%€21.30€16.56▼€24.90$7.40B0.51350,972 shs374,000 shsWRBYWarby Parker$18.49-2.1%$17.15$12.46▼$28.68$1.93B2.011.80 million shs3.13 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGKOSGlaukos-2.49%+5.39%+2.40%-35.88%-14.97%NARIInari Medical0.00%0.00%0.00%+0.06%+75.45%STVNStevanato Group+3.30%+14.97%+11.86%+21.92%+8.10%WRBYWarby Parker-2.09%+13.68%+24.72%-29.35%+19.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGKOSGlaukos4.6835 of 5 stars4.42.00.04.44.12.50.6NARIInari MedicalN/AN/AN/AN/AN/AN/AN/AN/ASTVNStevanato Group1.0189 of 5 stars0.01.01.70.02.70.01.9WRBYWarby Parker2.996 of 5 stars3.33.00.00.02.04.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGKOSGlaukos 2.75Moderate Buy$134.6746.04% UpsideNARIInari Medical 2.14Hold$69.22-13.44% DownsideSTVNStevanato Group 2.86Moderate BuyN/AN/AWRBYWarby Parker 2.69Moderate Buy$22.0018.98% UpsideCurrent Analyst Ratings BreakdownLatest WRBY, STVN, GKOS, and NARI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025WRBYWarby ParkerUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$23.00 ➝ $20.005/9/2025WRBYWarby ParkerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.005/9/2025WRBYWarby ParkerTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $22.005/6/2025GKOSGlaukosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.005/2/2025GKOSGlaukosStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.005/1/2025GKOSGlaukosTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$140.00 ➝ $135.005/1/2025GKOSGlaukosStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $115.005/1/2025GKOSGlaukosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$176.00 ➝ $115.005/1/2025GKOSGlaukosWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$160.00 ➝ $86.005/1/2025WRBYWarby ParkerTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.004/30/2025WRBYWarby ParkerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$23.00 ➝ $17.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGKOSGlaukos$404.52M13.03N/AN/A$9.46 per share9.75NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91STVNStevanato Group$1.10B6.70€1.02 per share23.97€4.15 per share5.88WRBYWarby Parker$795.09M2.43N/AN/A$3.08 per share6.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGKOSGlaukos-$134.66M-$2.37N/AN/AN/A-39.04%-16.53%-10.61%7/30/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/ASTVNStevanato Group$157.62M€0.5151.9642.107.1810.47%9.86%5.79%N/AWRBYWarby Parker-$63.20M-$0.12N/A184.90N/A-4.39%-8.26%-4.37%N/ALatest WRBY, STVN, GKOS, and NARI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million3/6/2025Q4 2024STVNStevanato Group€0.20€0.20N/A€0.19€346.26 million€352.68 million2/20/2025Q4 2024GKOSGlaukos-$0.38-$0.40-$0.02-$0.60$100.72 million$105.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGKOSGlaukosN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/ASTVNStevanato Group€0.060.25%N/A11.76%1 YearsWRBYWarby ParkerN/AN/AN/AN/AN/ALatest WRBY, STVN, GKOS, and NARI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025STVNStevanato Groupannual€0.060.3%6/5/20256/5/20257/17/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGKOSGlaukos0.195.544.71NARIInari MedicalN/A1.771.40STVNStevanato Group0.221.811.21WRBYWarby ParkerN/A2.472.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGKOSGlaukos99.04%NARIInari Medical90.98%STVNStevanato GroupN/AWRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipGKOSGlaukos5.80%NARIInari Medical10.60%STVNStevanato Group0.70%WRBYWarby Parker26.55%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGKOSGlaukos78057.14 million51.61 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableSTVNStevanato Group4,650302.84 million300.72 millionOptionableWRBYWarby Parker3,030104.50 million74.67 millionOptionableWRBY, STVN, GKOS, and NARI HeadlinesRecent News About These CompaniesAre Options Traders Betting on a Big Move in Warby Parker (WRBY) Stock?May 13 at 8:26 PM | msn.comD. E. Shaw & Co. Inc. Purchases 199,235 Shares of Warby Parker Inc. (NYSE:WRBY)May 13 at 6:02 AM | marketbeat.comWarby Parker (NYSE:WRBY) Shares Gap Up After Analyst UpgradeMay 13 at 1:13 AM | americanbankingnews.comTelsey Advisory Group Cuts Warby Parker (NYSE:WRBY) Price Target to $22.00May 12 at 2:17 AM | americanbankingnews.comHow some early feedback put Warby Parker on the path to successMay 11 at 1:59 PM | msn.comWarby Parker (NYSE:WRBY) Price Target Cut to $22.00 by Analysts at Telsey Advisory GroupMay 11 at 9:08 AM | marketbeat.comDriehaus Capital Management LLC Grows Stake in Warby Parker Inc. (NYSE:WRBY)May 11 at 6:50 AM | marketbeat.comAlgert Global LLC Reduces Stake in Warby Parker Inc. (NYSE:WRBY)May 11 at 4:57 AM | marketbeat.comWarby Parker (NYSE:WRBY) Price Target Raised to $20.00 at The Goldman Sachs GroupMay 11 at 2:23 AM | americanbankingnews.comWarby Parker Inc. (WRBY) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comEarnings call transcript: Warby Parker Q1 2025 results reveal revenue growthMay 10, 2025 | uk.investing.comWarby Parker Inc. (WRBY): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside PotentialMay 10, 2025 | finance.yahoo.comWarby Parker Inc (WRBY) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...May 9, 2025 | finance.yahoo.comDurable Capital Partners LP Has $218.32 Million Holdings in Warby Parker Inc. (NYSE:WRBY)May 9, 2025 | marketbeat.comWarby Parker Inc. (WRBY): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside PotentialMay 9, 2025 | insidermonkey.comCommit To Buy Warby Parker At $10, Earn 8.8% Annualized Using OptionsMay 8, 2025 | nasdaq.comWarby Parker (NYSE:WRBY) Reports Sales Below Analyst Estimates In Q1 EarningsMay 8, 2025 | finance.yahoo.comHow Warby Parker CEO started billion-dollar eyewear brand at homeMay 8, 2025 | youtube.comWarby Parker (WRBY) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 8, 2025 | zacks.comWarby Parker Inc. (WRBY) Matches Q1 Earnings EstimatesMay 8, 2025 | zacks.comBosun Asset Management LLC Has $2.23 Million Holdings in Warby Parker Inc. (NYSE:WRBY)May 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWRBY, STVN, GKOS, and NARI Company DescriptionsGlaukos NYSE:GKOS$92.21 -2.43 (-2.57%) As of 05/13/2025 03:59 PM EasternGlaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.Stevanato Group NYSE:STVN€24.42 +0.76 (+3.21%) As of 05/13/2025 03:52 PM EasternStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.Warby Parker NYSE:WRBY$18.49 -0.39 (-2.07%) As of 05/13/2025 03:59 PM EasternWarby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
